The latest price target for AnaptysBio (NASDAQ:ANAB) was reported by JP Morgan on November 12, 2024. The analyst firm set a price target for $66.00 expecting ANAB to rise to within 12 months (a possible 211.76% upside). 21 analyst firms have reported ratings in the last year.

The latest analyst rating for AnaptysBio (NASDAQ:ANAB) was provided by JP Morgan, and AnaptysBio maintained their overweight rating.

The last upgrade for AnaptysBio Inc happened on July 19, 2024 when JP Morgan raised their price target to $69. JP Morgan previously had a neutral for AnaptysBio Inc.

The last downgrade for AnaptysBio Inc happened on January 6, 2023 when Raymond James changed their price target from N/A to N/A for AnaptysBio Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of AnaptysBio, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for AnaptysBio was filed on November 12, 2024 so you should expect the next rating to be made available sometime around November 12, 2025.

While ratings are subjective and will change, the latest AnaptysBio (ANAB) rating was a maintained with a price target of $75.00 to $66.00. The current price AnaptysBio (ANAB) is trading at is $21.17, which is out of the analyst’s predicted range.